Triple-negative breast cancers make up 10%–20% of advanced breast cancers, resulting in loss of efficacy of treatments targeting estrogen or progesterone receptors and human epidermal growth factor receptor 2 (Kumar and Aggarwal, 2016; Cardoso et al, 2017). This evidence concerns the gene PGR and breast carcinoma.